Skip to main navigation Skip to search Skip to main content

Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2

  • Rui Liu
  • , Rui Yang
  • , Xuezhu Xu
  • , Wanhong Zhao
  • , Fangxia Wang
  • , Wanggang Zhang
  • , Bo Lei
  • , Ruoyu Yang
  • , Yiwen Wang
  • , Aili He
  • , Jianli Wang
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Xi’an Key Laboratory of Diagnosis and Treatment of Hematological Diseases

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has shown profound efficacy and manageable toxicity in patients with relapsed/refractory multiple myeloma (RRMM). However, determining the best course of treatment for post-CAR-T therapy relapse remains a significant challenge. We conducted a retrospective analysis of patients from the phase I LEGEND-2 study (NCT03090659) enrolled at the Xi'an site, analysing the first salvage line of therapy and outcomes in patients with RRMM who progressed after receiving LCAR-B38M CAR-T therapy. Of 45 eligible patients, 34 (76%) had progressive disease (PD). Overall response rate (ORR) to salvage treatment was 50.0%. Median progression-free survival (PFS) after starting salvage treatment was 16.3 months. Median PFS of patients receiving proteasome inhibitor (PI)-based combination therapy was longer (28.2 months) than that of patients receiving a second BCMA CAR-T (including LCAR-B38M; 3.9 months, p = 0.0022) or chemotherapy (1.67 months, p = 0.0001). All patients with extramedullary disease at baseline (n = 11) progressed after CAR-T therapy; ORR to salvage therapy was 25.0% and median PFS was 9.7 months. In conclusion, salvage therapy in patients with PD after receiving LCAR-B38M CAR-T cells produced moderate efficacy, with better outcomes for PI-based salvage regimens.

Original languageEnglish
Pages (from-to)1780-1789
Number of pages10
JournalBritish Journal of Haematology
Volume204
Issue number5
DOIs
StatePublished - May 2024

Keywords

  • CAR-T therapy
  • multiple myeloma
  • progress
  • salvage treatment

Fingerprint

Dive into the research topics of 'Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA-specific CAR-T therapy: A retrospective analysis of LEGEND-2'. Together they form a unique fingerprint.

Cite this